Clinical Trials
Daily Coffee Consumption Linked to Reduced AFib Recurrence in New Clinical Trial
A new clinical trial reveals that adults with atrial fibrillation who drank one cup of coffee daily were 39% less likely to experience recurrent AFib episodes, challenging conventional medical advice about caffeine avoidance for heart rhythm patients.
Catheter Ablation May Eliminate Need for Blood Thinners in Some AFib Patients, Study Finds
New research suggests successful catheter ablation for atrial fibrillation reduces stroke risk enough that many patients can safely discontinue potent blood thinners in favor of aspirin, potentially reducing bleeding complications while maintaining stroke protection.
Shorter Clot-Prevention Therapy After Stent Placement Proves Effective for AFib Patients
New research shows a one-month course of dual clot-preventing therapy followed by single medication treatment is as effective as year-long dual therapy for preventing stroke, heart attack and death in atrial fibrillation patients with stents, while significantly reducing bleeding complications.
Standard Medical Care Outperforms Minimally Invasive Procedure for High-Risk Atrial Fibrillation Patients
New research presented at the American Heart Association's Scientific Sessions 2025 found that standard medical care, including blood thinners when appropriate, proved more effective than a catheter-based procedure for preventing stroke and other complications in older atrial fibrillation patients at high risk of bleeding and stroke.
Oral Cholesterol Medication Shows Promise as Alternative to Injectable Treatments
A new daily oral medication called enlicitide demonstrated up to 60% reduction in LDL cholesterol in clinical trials, potentially offering a more convenient option for high-risk patients who struggle to reach cholesterol targets with current treatments.
CRISPR Gene-Editing Therapy Shows Promise in Lowering Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human trial of CTX310, a CRISPR-based gene-editing therapy, demonstrated significant reductions in LDL cholesterol and triglycerides with sustained effects, potentially offering a one-time alternative to daily medications for patients with difficult-to-treat lipid disorders.
PCSK9 Inhibitor Shows Significant Cardiovascular Risk Reduction in High-Risk Patients Without Prior Heart Events
The VESALIUS-CV trial demonstrates that evolocumab reduces major cardiovascular events by 25% in patients with atherosclerotic disease or diabetes who haven't had prior heart attacks or strokes, potentially expanding preventive treatment options for millions at risk.
Novel Triple-Receptor Medication Shows Promise for Severe Triglyceride Reduction and Liver Health
A new investigational medication called DR10624 demonstrated significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia, potentially offering a new treatment approach for a condition with limited current options.
Oncotelic Therapeutics Venture Advances Novel Breast Cancer Treatment to Clinical Trials
Sapu Nano, an Oncotelic Therapeutics venture, has received Australian ethics approval to begin clinical trials for Sapu003, an injectable form of everolimus that could significantly improve breast cancer treatment outcomes by enabling full drug absorption through intravenous delivery.
Soligenix Reports Q3 2025 Results with Key Clinical Milestones for Rare Disease Treatments
Soligenix Inc. announced positive clinical progress for its rare disease pipeline including upcoming Phase 2a psoriasis results and maintained safety profile for HyBryte™ in CTCL treatment, supported by sufficient funding through 2026.
Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
Soligenix is progressing its phase 2a clinical trial of SGX302 for psoriasis treatment, showing encouraging safety and biological activity data that positions the therapy to address a $67 billion global market opportunity.
Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Cybin Inc. to Present at Guggenheim Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development
Cybin Inc. announced its participation in the Guggenheim Healthcare Innovation Conference as the company advances its Phase 3 clinical trials for novel mental health treatments, highlighting growing investor interest in innovative neuropsychiatry solutions.
NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push
NanoViricides announced its 2025 shareholders meeting while advancing multiple antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline
Soligenix has strengthened its financial position with strategic capital initiatives, providing runway through 2026 to advance multiple late-stage therapeutic and vaccine candidates addressing rare diseases and biodefense needs.
Kairos Pharma Reports Promising Phase 2 Results for Prostate Cancer Treatment ENV105
Kairos Pharma's ENV105 demonstrates 86% clinical benefit rate in advanced metastatic prostate cancer patients when combined with standard therapy, potentially addressing critical treatment resistance challenges in oncology.
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Sapu Nano Announces First Human Trial of Injectable Everolimus Formulation for Breast Cancer
Sapu Nano has revealed initial human clinical trials for Sapu-003, an intravenous formulation of Everolimus that could offer improved bioavailability and efficacy compared to oral versions for breast cancer treatment.
Soligenix Strengthens CTCL Advisory Board to Advance HyBryte Therapy Development
Soligenix has updated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma to support the clinical advancement of HyBryte and related therapies, reflecting the company's strategic focus on navigating complex regulatory and commercialization challenges in the rare disease space.
American Heart Association Launches Initiative to Accelerate Aortic Stenosis Diagnosis and Clinical Trial Access
The American Heart Association has launched a new initiative to improve early diagnosis of aortic stenosis and increase participation in clinical trials, potentially transforming care for this serious heart condition that often goes undiagnosed until advanced stages.
NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
Cybin Secures $175 Million in Funding to Advance Mental Health Therapeutics
Cybin Inc. has closed a $175 million registered direct offering with top healthcare investors, providing critical capital to advance its Phase 3 clinical programs for novel mental health treatments addressing major depressive disorder and generalized anxiety disorder.
Cybin Chief Medical Officer to Present at Prestigious 2025 Milken Institute Health Summit
Cybin Inc.'s Chief Medical Officer will participate in the 2025 Milken Institute Future of Health Summit, highlighting the company's advanced clinical-stage mental health treatments and their potential to address significant unmet medical needs.
GeoVax Relocates Headquarters and Labs to Atlanta Area to Fuel Growth and Pipeline Advancement
GeoVax Labs is relocating its corporate headquarters and laboratory operations to new Atlanta-area facilities, positioning the clinical-stage biotechnology company for accelerated growth, late-stage development, and future commercialization of its cancer and infectious disease therapies.
Combining Healthy Lifestyle Habits with GLP-1 Medications Reduces Cardiovascular Risk in Type 2 Diabetes Patients
A study of over 63,000 veterans with Type 2 diabetes found that combining GLP-1 receptor agonist medications with at least six healthy lifestyle habits reduced cardiovascular event risk by 50% compared to standard care alone.
Low-Dose Aspirin Shows Cardiovascular Benefits for High-Risk Type 2 Diabetes Patients
A preliminary study suggests adults with Type 2 diabetes and moderate-to-high cardiovascular risk who take low-dose aspirin experience significantly lower rates of heart attack, stroke, and death compared to non-users, though bleeding risks require careful consideration.
Cybin Secures $175 Million in Registered Direct Offering to Advance Mental Health Treatments
Cybin Inc. has raised $175 million through a registered direct offering, providing crucial funding to advance its late-stage clinical trials for novel mental health treatments including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder.
Lifordi Immunotherapeutics Advances Glucocorticoid ADC LFD-200 into Phase 1 Rheumatoid Arthritis Trial Following Promising Nonclinical Data
Lifordi Immunotherapeutics has initiated Phase 1 clinical trials for LFD-200, a novel antibody-drug conjugate that delivers glucocorticoids directly to immune cells, potentially overcoming the systemic toxicity limitations that have restricted steroid use in autoimmune diseases for decades.
Oncotelic Therapeutics to Present Novel Breast Cancer Treatment Data at 2025 Symposium
Oncotelic Therapeutics will present clinical data for its investigational breast cancer treatment Sapu003 at the 2025 San Antonio Breast Cancer Symposium, potentially offering improved efficacy and reduced toxicity for patients with HR⁺/HER2⁻ metastatic breast cancer.
GeoVax Vaccine Data Aligns With New IDSA Guidelines for Protecting Immunocompromised Patients
GeoVax's GEO-CM04S1 vaccine demonstrates robust T-cell responses and cross-variant durability in immunocompromised populations, addressing critical gaps identified in new IDSA guidelines that show current COVID-19 vaccines provide only moderate, short-lived protection for vulnerable patients.